Rethinking Schering
May 1st, 2008 by Grant in: InvestingI started reading over the Schering-Plough (SGP: chart, web, Y!) 2007 financial report in an effort to do some more research.
Interestingly enough, I’m starting to rethink my position on Schering. SGP had really fallen out of favor with me since the whole Vytorin mess really blew up, and the stock price sunk to $13.83 per share for its 52 week lows.
After digesting some of the numbers though, I don’t think things look all that bad… at least not bad enough to justify the $18 share price.
Back in November of last year, Schering bought Organon BioSciences (OBS) for about $16.1 billion. Effectively, that entire acquisition went on the books for the entire year.
With that purchase came $3.8 billion worth of acquisition in-process research and development stemming from Organon’s women’s health and animal research. Effectively this was the cost of doing the research for up and coming drugs relating to women’s health and animal health.
Effectively, this in-process research and development cost was reflected in the $1.04 per share loss for fiscal 2007. If you look past those costs, Schering turns a healthy profit.
The fact is, you do have to weigh in those R&D costs when refining the value of a company, and as such whether or not to buy stake in the company. However, so long as there is a return on your R&D, it’s money well spent.
And there-in lies the big dilemma: Will Schering see appreciable returns on the $3.8 billion R&D hit from 2007?
My gut says yes, but the headlines say no.
The FDA is in the drivers seat right now, as they should be. I’m not too wound up about the Vytorin study, as the company has diversified its product line enough to make up for those lost sales. However, recent headlines from Merck make it all too obvious that standards are being tightened in the pharma sector.
The short story is that I think Schering Plough is undervalued below $25, and I think I’ll start buying in small chunks. If it crosses the $25 mark before next quarters earnings report, I’ll sell half my stake and let the rest ride through earnings.
The company reported Q1 2008 earnings of $0.53 per share, which blew away the estimates of $0.37. I like that, and I think that trend will continue.
Comments:
Subscribe to Comments
















